a b s t r a c t SB269652 is a negative allosteric modulator of the dopamine D 2 receptor (D 2 R) yet possesses structural similarity to ligands with a competitive mode of interaction. In this study, we aimed to understand the ligand-receptor interactions that confer its allosteric action. We combined site-directed mutagenesis with molecular dynamics simulations using both SB269652 and derivatives from our previous structure activity studies. We identify residues within the conserved orthosteric binding site (OBS) and a secondary binding pocket (SBP) that determine affinity and cooperativity. Our results indicate that interaction with the SBP is a requirement for allosteric pharmacology, but that both competitive and allosteric derivatives of SB269652 can display sensitivity to the mutation of a glutamate residue (E95 2.65 ) within the SBP. Our findings provide the molecular basis for the differences in affinity between SB269652 derivatives, and reveal how changes to interactions made by the primary pharmacophore of SB269652 in the orthosteric pocket can confer changes in the interactions made by the secondary pharmacophore in the SBP. Our insights provide a structure-activity framework towards rational optimization of bitopic ligands for D 2 R with tailored competitive versus allosteric properties.
Introduction
The dopamine D 2 receptor (D 2 R), a prototypical class A G protein-coupled receptor (GPCR), is a therapeutic target for a variety of central nervous system disorders [1] . To date, drug discovery at the D 2 R has focused on targeting the conserved orthosteric binding site (OBS), either with agonists for the treatment of the motor symptoms of Parkinson's disease, or antagonists for the treatment of the positive symptoms of schizophrenia [2] . However, this approach can be associated with significant adverse side effects. In particular, the orthosteric blockade of the D 2 R by typical antipsychotics, while effective in treating the positive symptoms of schizophrenia, is associated with extrapyramidal side effects [2] .
It is now apparent that many class A GPCRs possess topographically distinct, allosteric binding sites that have the potential to be targeted by small molecules [3] [4] [5] . Allosteric targeting may offer several advantages over purely orthosteric ligands, including increased subtype selectivity afforded by the lower degree of sequence conservation at these sites, and maintenance of the spatiotemporal patterns associated with endogenous neurohumoral signalling [6] . These potential advantages make allosteric targeting of the D 2 R an attractive approach for the treatment of schizophrenia, for which partial blockade by a negative allosteric modulator (NAM) with limited negative cooperativity could be safer and associated with fewer side effects. However, despite the potential of allosteric modulators, this approach has yet to be exploited therapeutically. This is due, in part, to the paucity of allosteric scaffolds that act at the D 2 R. In addition, there is only limited information about the location and druggability of allosteric binding site(s) within this receptor [7] .
Recently, we demonstrated that the compound SB269652 is a NAM of the D 2 R, and presented a novel allosteric mechanism whereby SB269652 adopts a bitopic pose at one protomer of a D 2 R dimer to modulate the binding of dopamine at the adjacent protomer [8] . To this end, molecular modelling and site-directed mutagenesis experiments have revealed a secondary binding pocket (SBP) at the extracellular ends of transmembrane segments (TMs) 2 and 7 that accommodates the indole-2-carboxamide secondary pharmacophore (SP) of SB269652 [8, 9] . Our molecular modelling studies predict that E95
2.65 (Ballesteros-Weinstein nomenclature [10] ), which sits at the water-accessible surface at the extracellular end of TM2, forms a hydrogen-bond interaction with the indolic NH of SB269652. This prediction was validated by the mutation E95 2.65 to alanine, which results in a significant loss in SB269652 affinity and negative cooperativity with dopamine [8] . The observation that methylation of the indole NH, thus abrogating the ability to hydrogen bond with E95 2.65 , results in a derivative that displays pharmacology best fitted by a competitive model provided further evidence that this interaction plays a critical role in determining the allosteric pharmacology of SB269652 [8] .
The antagonist-bound crystal structure of the highly homologous D 3 R revealed a SBP comprising residues from the extracellular ends of TMs 1, 2, 3, and 7 and extracellular loops (ECLs) 1 and 2 [11] . Subsequent studies have revealed that the subtypeselectivity of extended ligands such as R-22 is conferred by the interaction of the SP of such ligands with this SBP [12] . It should be noted that although R-22 displays competitive pharmacology, the 1H-indole-2-carboxamide SP of R-22 is identical to that of SB269652. Thus, the allosteric action of SB269652 is not simply conferred by its extension into this SBP but instead must be conferred by differences in the receptor-ligand interactions made by these two structurally related-ligands [12] . In agreement with this observation, our structure-activity studies of SB269652 revealed that relatively subtle changes to the orthosteric tetrahydroisoquinoline (THIQ) primary pharmacophore, the linker region, or the SP all had profound affects upon cooperativity and/or affinity, and could even lead to a change from allosteric to apparently competitive pharmacology [9] . Therefore, to exploit this novel class of allosteric modulator at the D 2 R, it is important to understand the ligand-receptor interactions that confer this allosteric pharmacology and the differences in the binding modes of structurally similar competitive antagonists. In this study, we investigated the structural basis for the allosteric mechanism of SB269652 by combining site-directed mutagenesis with molecular modelling and simulations of D 2 R in complex with either SB269652 or its selected derivatives.
Methods and materials

Materials
SB269652 and all derivatives were synthesised as previously described and were shown to be >95% pure [8, 9] . Dopamine was purchased from Sigma-Aldrich (Castle Hill, NSW, Australia) and was >98% pure as indicated by the supplier. Dulbecco's modified Eagle's medium (DMEM), hygromycin B, and FlpIn CHO cells were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from ThermoTrace (Melbourne, VIC, Australia). [ 3 H] Spiperone, AlphaScreen reagents, Ultima gold scintillation cocktail, and 384-well proxiplates were purchased from PerkinElmer (Boston, MA). All the other reagents were purchased from SigmaAldrich (Castle Hill, NSW, Australia).
Synthesis of compounds
All compounds were synthesised as described in Shonberg et. al. 2015 with the exception of MIPS1868 which was synthesised as follows.
To a stirred solution of 2-(2-((trans)-4-aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (126 mg, 444 mmol) and 7-fluoro-1H-indole-2-carboxylic acid (95.5 mg, 533 mmol) in a minimal volume of anhydrous DMF (3-4 mL) was added the coupling reagent, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b ]pyridinium 3-oxid hexafluorophosphate (HATU, 253 mg, 666 mmol) and an excess of DIPEA. The reaction was stirred at room temperature overnight after which time, LCMS revealed complete consumption of starting material. The reaction mixture was then diluted with 30 mL of a 1:1 mixture of a saturated solution of NaHCO 3 and water and left to stir for a further 30 min. The resulting precipitate was filtered, washed with water, dried and then recrystallised via hot filtration in a mixture of MeOH and water to yield the title compound as a beige crystalline solid (112 mg, 57% 
Molecular biology
cDNA in pcDNA3.1+ encoding the long isoform of the wild-type human dopamine D 2 receptor (D 2L R) was obtained from Missouri University of Science and Technology (http://www.cdna.org/). An N-terminal c-Myc epitope tag (EQKLISEEDL) was inserted into the sequence of the D 2L R via overlap extension PCR. The receptor construct in pcDNA3.1+ was transferred into the hygromycin resistance gene containing pEF5/frt/V5/dest vector using the LR clonase enzyme mix (Invitrogen). Oligonucleotides were purchased from GeneWorks (Hindmarsh, Australia). Desired mutations were introduced using the Quikchange site-directed mutagenesis kit (Agilent, Santa Clara, CA). The manufacturer's instructions were followed with the exception of the number of oligonucleotides used, their concentration and the concentration of the template DNA. Either two primers (200 nM of each) were used with 50 ng of c-Myc D 2L R template, or alternatively one primer (1 lM) with 200 ng of c-Myc D 2L R template was used. All mutations were confirmed by DNA sequencing (Australian Genome Research Facility, Melbourne, Australia).
Cell lines and transfections
Flp-In-CHO cells were grown in DMEM supplemented with 10% fetal bovine serum and maintained at 37°C in a humidified incubator containing 5% CO 2 . The Flp-In-CHO cells were transfected with the pOG44 vector encoding Flp recombinase and the pDEST vector encoding the wild-type or mutant c-Myc-D 2L R at a ratio of 9:1 using polyethylenimine as transfection reagent. 24 h after transfection the cells were subcultured and the medium was supple-mented with 700 lg/ml hygromycin B as selection agent to obtain cells stably expressing the c-Myc-D 2L R.
ERK1/2 phosphorylation assay
In our Flp-In-CHO cell line stably expressing the human D 2L R, the pERK1/2 response is abrogated by pertussis toxin treatment (data not shown). Thus, this provides a convenient downstream measurement of Ga i/o protein activation. ERK1/2 phosphorylation was measured using the Alphascreen TM SureFire ERK kit (PerkinElmer, Waltham, USA). Cells were seeded into 96-well plates at a density of 50,000 cells/well. After 4-6 h, cells were washed with PBS and incubated in serum-free DMEM (pH 7.4) overnight before assaying. Interaction experiments were performed for each ligand at 37°C in the presence of 0.1% ascorbic acid. SB269652 or derivative of interest was pre-equilibrated with cells for 30 min prior to agonist stimulation. Stimulation of the cells was terminated after 5 min of agonist exposure by removing the media and the addition of 100 ll of SureFire lysis buffer to each well. The plate was shaken for 5 min at room temperature before transferring 5 ll of the lysates to a white 384-well Proxiplate (PerkinElmer, Waltham, USA). Then 8 ll of a 240:1440:7:7 mixture of Surefire activation buffer: Surefire reaction buffer: Alphascreen acceptor beads: Alphascreen donor beads was added to the samples and incubated in the dark at 37°C for 1.5 h. Plates were read using a Fusion-TM plate reader (PerkinElmer, Waltham, USA).
Membrane preparation
Flp-In-CHO cells stably expressing the wild-type or mutant cMyc-D 2L R were grown to 90% confluency in 175 cm 2 cell culture flasks or 500 cm 2 cell culture dishes (Corning, Corning, NY). The cells were harvested in PBS containing 2 mM EDTA and centrifuged at 300g for 3 min. The resulting pellet was resuspended in assay buffer (20 mM HEPES, 100 mM NaCl, 6 mM MgCl 2 , 1 mM EGTA and 1 mM EDTA, pH 7.4, 4°C) and the centrifugation step was repeated. The intact cell pellet was then resuspended in assay buffer and homogenized using a Polytron homogenizer. After centrifugation (350g, 5 min) the pellet was discarded, and the supernatant was recentrifuged at 30,000g for 1 h at 4°C using a Sorvall Evolution RC ultracentrifuge (Thermo Scientific, Waltham, MA). The resulting pellet was resuspended in assay buffer and stored in 500 ll aliquots at À80°C. Membrane protein concentration was determined using the method of Bradford.
[ 3 H]spiperone binding assays
All radioligand binding experiments were conducted in a 1 mL reaction volume in assay buffer (20 mM HEPES, 100 mM NaCl, 6 mM MgCl 2 , 1 mM EGTA and 1 mM EDTA, pH 7.4) containing 100 lM GppNHp and 0.1% ascorbic acid. In all cases non-specific binding was determined in the presence of 10 lM haloperidol. To obtain affinity estimates of unlabelled agonists, competitionbinding experiments were performed at equilibrium. The ability of increasing concentrations of the agonists to compete with 0.1 nM [ 3 H]spiperone for binding to the wild-type or mutant c-Myc-D 2L R was tested. The membranes (5 lg) were incubated with the drugs for 3 h at 37°C. After this incubation period, bound and free radioligand were separated by fast-flow filtration through GF/B filters using a Brandel harvester followed by three washes with icecold 0.9% NaCl. Filter bound radioactivity was measured by scintillation spectrometry after the addition of 3.5 mL of Ultima Gold (PerkinElmer) using a Tri-Carb 2900TR liquid scintillation counter (PerkinElmer).
Molecular modelling and simulations
The binding mode of SB269652 and its derivatives in the D 2 R were investigated based on our previous study [8] . Briefly, assuming similar binding modes of the THIQ moiety in the near-identical OBSs of D 3 R and D 2 R, the pose from the induced-fit docking (IFD) [13] trial with our previous equilibrated D 2 R model [11, 12] that is closest to the reference pose in our D 3 R model was selected. The full-length SB269652 was then docked into the D 2 R model by a core-restrained IFD protocol [12, 13] with restraints on the heavy atoms (heavy-atom RMSD deviation <2.0 Å) of the selected THIQ pose. Representative poses for the SB269652 derivative compounds, were acquired similarly by using the core-restrained IFD protocol, where restraints were applied on the THIQ moiety of the full-length SB269652, assuming that this moiety adopts a similar pose in SB269652 derivatives as well.
Molecular dynamics (MD) simulations of the D 2 R-ligand complexes were performed in the explicit water and 1-palmitoyl-2-ol eoylphosphatidylcholine lipid bilayer solvent environment using the Desmond MD system (version 4.5-4.8; D. E. Shaw Research, New York, NY) with the CHARMM36 protein force field [14] [15] [16] , CHARMM36 lipid force field [17] , and TIP3P water model. The ligand parameters were obtained from the GAAMP server [18] , with the initial force field based on CGenFF assigned by ParamChem [19] . The system charges were neutralized, and a solvent concentration of 150 mM NaCl was added. The average system size is $111,000 atoms. Each system was first minimized and then equilibrated with restraints on the ligand heavy atoms and protein backbone atoms, followed by an isothermal-isobaric simulation at 310 K with all atoms unrestrained, as described previously [20, 21] . We collected multiple trajectories for each complex, and the total simulation lengths for each complex were summarized in Table 1 .
Data analysis
Radioligand binding data: For radioligand saturation binding data, the following equations were globally fitted to total binding (1) and nonspecific binding (2) data respectively:
where Y is radioligand binding, B max is the total receptor density, [A] is the free radioligand concentration, K A is the equilibrium dissociation constant of the radioligand, and NS is the fraction of nonspecific radioligand binding.
Competition-binding curves between [
3 H]spiperone and dopamine in the absence or presence of SB269652 were fitted to a one-site binding equation [22] : Functional data: A logistic equation of competitive agonist-antagonist interaction was globally fitted to data from functional experiments measuring the interaction between dopamine and all analogues of SB269652 [25] :
where s represents the Schild slope for the antagonist, and pA 2 represents the negative logarithm of the molar concentration of antagonist that makes it necessary to double the concentration of agonist needed to elicit the original submaximal response obtained in the absence of antagonist. Functional data describing the interaction between all SB269652 analogues and dopamine analysed according to the allosteric ternary complex model [3] :
where E m is the maximum possible cellular response, [A] and [B] are the concentrations of orthosteric and allosteric ligands, respectively, and K B are the equilibrium dissociation constant of the orthosteric and allosteric ligands, ab is a composite cooperativity parameter between the orthosteric and allosteric ligand that includes effects upon orthosteric ligand affinity and efficacy and nH is the Hill slope of the orthosteric agonist concentrationresponse curve. Values of a and/or b greater than 1 denote allosteric potentiation, whereas values less than 1 (but greater than 0) denote allosteric inhibition. For each of the compounds the two equations (models) were then compared for their fit using an extra-sum-of-squares F test, whereby the simpler model was selected unless the P value was less than .05.
Results
Effect of mutations upon the actions of orthosteric ligands
In order to characterize the effects of the various OBS and SBP mutations on orthosteric ligands, we performed radioligand binding assays using the antagonist [ [30] . Saturation-binding experiments revealed that the remaining 31 mutants were expressed to similar levels to WT ( Table 2 ). In addition, 11 of the D 2 R mutants significantly decreased dopamine potency ( ) have been previously shown to be important for agonist binding and efficacy [30] [31] [32] . The conserved TM5 serine residues (5.42, 5.43 and 5.46) interact with the meta-OH and para-OH moieties of catecholamine agonists [33, 34] . No dopamine response was observed at the D114 3.32 E, S193 5.42 A, or S197 5.46 A mutants (Table 2) . It is interesting to note that mutation of Leu41 A, Table 2 ). While these effects require further investigation, the binding affinity of dopamine at the T412 7.39 A mutant was significantly higher that for the WT whereas it is unchanged for I184 ECL2 -A (Table 2 ). This suggests that the decrease in potency observed at the two mutants is not caused by a decrease in agonist affinity but rather may reflect a role for these residues in signal transduction.
The interaction of SB269652 with the SBP is important for both affinity and cooperativity
The 1H-indole-2-carboxamide SP of SB269652 extends into a SBP between the extracellular ends of TMs 1, 2 and 7, and ECL1 and ECL2 [8] . To identify the receptor-ligand contacts within the SBP that are important for the binding and cooperativity of SB269652, SBP residues were mutated to alanine. The mutation Y37
1.35 A did not significantly alter the affinity or cooperativity of SB269652 whereas the mutation L41 1.39 A, a turn down from Y37 1.35 , caused a significant 11-fold increase in functional affinity of SB269652 ( Fig. 1 , Table 3 ). T412 7.39 A, at the extracellular end of TM7, also significantly increased both binding and functional affinity of SB269652 (14-and 9-fold, respectively, Table 3 ). Interestingly, in binding experiments, there was a significant enhancement in the negative cooperativity between SB269652 and [ 3 H] spiperone at both L41 1.39 A and T412
7.39 A (3-fold, Table 3 ). In contrast, the affinity and negative cooperativity of SB269652 was not altered at S409 7.36 A or F411 7.38 A (Table 3 ). In agreement with our previous study, we observed a significant loss of binding affinity, functional affinity and negative cooperativity upon mutation of E95
2.65
A at Table 3 ). In addition, the mutation L94 and V91 2.61 line the hydrophobic interface between the OBS and the SBP. Mutation of these residues causes a significant loss in negative cooperativity with dopamine but no significant change in affinity (Table 3) . There is evidence that interaction with ECLs1 and 2 determines the subtype selectivity of SB269652 [26] . In addition ECL1 and 2 residues form part of an allosteric pocket at muscarinic acetylcholine receptors, contribute directly to orthosteric ligand binding at the D 2 R, and line the pathway of ligand entry and egress at aminergic receptors [27] [28] [29] .To understand the importance of these loops for the binding and action of SB269652, we extended our mutagenesis study to ECL 1 and 2 residues. The mutations G98A or K101A in ECL1 significantly increased the functional affinity (15-and 9-fold, respectively) of SB269652, and K101A significantly increased negative cooperativity with dopamine (3-fold, Table 3 ). In contrast, these mutations had no effect on the binding affinity of SB269652, but G98A caused a 2-fold decrease in cooperativity with [ 3 H]spiperone. The mutations N180A and E181A in ECL2 significantly improved SB269652's functional affinity (5-and 11-fold, respectively) but not binding affinity (Table 3) . Together these data are consistent with the occupation of the SBP by SB269652 as predicted by our modelling studies and that this interaction is an important determinant of affinity and cooperativity (Fig. 1). 
SB269652 engages residues within the OBS of the D 2 R
We next turned our attention to identifying OBS residues that interact with SB269652 or that are important for its negative cooperativity with dopamine. Our molecular modelling predicts that the protonated aliphatic amine in the THIQ moiety of SB269652 forms a salt bridge with the conserved D114 3.32 , an interaction made by most orthosteric dopaminergic ligands. [8] . We observed no significant loss in binding affinity of SB269652 at the D114 Table 4 ). The mutation D114 3.32 E extends this residue by one carbon and retains the ability to form a salt bridge with the tertiary amine of dopaminergic ligands. The lack of an effect by the mutation D114 3.32 E upon the binding affinity of SB269652 suggests that the small THIQ core can accommodate the introduction of this slightly larger residue into the OBS. Indeed, while the D114 Table 1 ). The significant change in negative cooperativity of SB269652 at the D114 3.32 E mutant compared to WT, however, suggests that the orientation of SB269652 within the OBS pocket is a determinant of cooperativity (Fig. 1) . Mutation of H393 6 .55 (H393 6.55 A or H393 6.55 F), which lies at the periphery of the OBS, causes no significant change in SB269652 affinity or cooperativity (Table 4 ). F390 6.52 is positioned slightly deeper within the core of the OBS. F390 6.52 A resulted in a significant 6-fold increase in the functional affinity of SB269652, but no significant change in negative cooperativity with dopamine but a significant 2-fold increase in negative cooperativity with [ 3 H] spiperone (Table 4) . We next explored the influence of the three conserved serine residues in TM5. The mutation S197 5.46 A had no effect, whereas S194 5.43 A caused a significant 5-fold decrease in negative cooperativity with dopamine in the functional assay and significant 3-fold decrease in negative cooperativity with [ 3 H]spiperone but no change in affinity (Fig. 1, Table 4 ). Of note, we observed a significant increase in SB269652 binding affinity (31-fold) and negative accommodating the cyano group. This is supported by the corresponding changes from the ligand side where a derivative of SB269652 that lacks the cyano group displays increased affinity at the WT D 2 R (see below and Discussion). Substituted-cysteine accessibility studies at the D 2 R and the recent crystal structure of the D 3 R showed that ECL2 residues, and in particular I184, forms part of the OBS [11, 27] . In this study, while the mutation of the nearby residue, I183
ECL2
A has no effect, SB269652 gains significant affinity (9-fold) and negative cooperativity with dopamine (3-fold) at the I184 ECL2 A mutant, an effect observed in both binding and functional assays (Table 3 ). In addition, this mutation increases negative cooperativity with [ 3 H] spiperone 9-fold. Note that both S193 5.42 A and I184
A increase the affinity of [ 3 H]spiperone and cause a decrease in dopamine potency that may result from the stabilisation of a receptor conformation that favours antagonist binding ( Table 2 , Fig. 1 ). Stabilisation of such a conformation may also contribute to the increased affinity of SB269652 observed at these mutants. Our mutagenesis results reveal residues within the OBS and the SBP that determine the affinity of SB269652 and its cooperativity with orthosteric ligands, consistent with the extended bitopic binding pose predicted for SB269652. To understand how such a pose might explain the results of our previous SAR study, we next investigated the impact of mutations to a key residue within the OBS (D114 3.32 ) and a key residue within the SBP (E95 2.65 ) upon the action of a selected series of SB269652 derivatives and fragments.
Fragments and derivatives of SB269652 that contain the THIQ moiety interact with D114
3.32 within the OBS It was interesting to note that the significant loss of cooperativity with [ 3 H]spiperone at the D114 3.32 E mutant was not accompanied by a change in the affinity of SB269652. To gain further insight into the interaction of the THIQ primary pharmacophore with the OBS we extended our study to two fragments of SB269652: 2-pro pyl-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (MIPS1071), and N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)yl)ethyl)cy clohexyl)acetamide (MIPS1059, Table 6 ). Both fragments contain the THIQ core, act as competitive antagonists of dopamine, and displayed a significant loss of affinity at the D114 3.32 E mutant (230-fold and 100-fold, respectively), highlighting the importance of this residue for the binding of the THIQ scaffold within the OBS (Table 5 ) [8] .
The cooperativity of SB269652 with [ 3 H]spiperone is relatively weak, resulting in a small window to observe the effect of mutations, which may mask subtle effects. Therefore, we extended our study to MIPS1868, a higher-affinity SB269652 derivative that displays greater negative cooperativity with [ 3 H]spiperone (K B = 160 nM, a = 0.01, Table 5 ). Furthermore, MIPS1868 possesses the structural characteristics of SB269652 that we have found to be necessary for allosteric pharmacology (THIQ core, trans-cyclohexylene linker, hydrogen-bond donating heteroatom, and aromatic bicyclic tail) and differs from SB269652 simply through the substitution of a fluorine at the 7-position of the indole-2-carboxamide moiety [9] . MIPS1868 displayed a significant 4-fold loss in binding affinity at the D114 3.32 E mutant (Table 5) , consistent with a salt bridge interaction formed between this residue and the protonated aliphatic amine within the THIQ core of MIPS1868.
Linker length is critical for the correct engagement of the indole tail with E95 2.65
Derivatives of SB269652 in which the cyclohexylene spacer moiety was replaced with flexible polymethylene linkers were shown to display improved affinity as compared to SB269652. However, the length of the carbon spacer bridging the PP and SP was shown to determine allosteric pharmacology. A linker length of 3 or 4 carbon atoms conferred allosteric pharmacology but a 5-carbon linker length resulted in pharmacology best-fit by a competitive model [9] . We hypothesized that this difference in pharmacology could be conferred by a distinct orientation of the SP of the 5-carbon linker derivative, such that it does not interact with the SBP and in particular with E95 2.65 . We carried out MD simulations of D 2 R models in complex with either 4-carbon or 5-carbon linker derivatives (MIPS1529 and MIPS1546, respectively). The simulation results show that the 4-carbon linker (MIPS1529) permits an interaction of the indole moiety with the SBP and in particular the hydrogen-bond interaction between the indolic NH and E95 2.65 , while this interaction could not form in the simulations of the D 2 R bound with the 5-carbon linker derivative (MIPS1546, Fig. 2 ). Instead the indole moiety of this longer derivative is predicted to extend towards the subpocket of the SBP between TMs 2 and 3. Supporting this prediction, the 4-carbon linker derivative (MIPS1529, Fig. 2 ) displays a signif- icant loss in both functional affinity (8-fold) and negative cooperativity (9-fold) at the E95 2.62 A mutant (Table 6 , Fig. 2) . Conversely, the 5-carbon linker derivative (MIPS1546, Fig. 2 ) behaves as a competitive antagonist at the WT D 2 R (151 nM, Schild slope = 0.97 ± 0.05, Table 6 ) and its affinity is not significantly altered at the E95 2.65 A mutant (K B = 177 nM, Table 6 ). Consistent with these data, analysis of our MD simulation results shows a greater distance between the indolic NH and E95 2.65 for the 5-carbon linker derivative (MIPS1546) as compared to the 4-carbon linker derivative (MIPS1529). This is associated with a change in the orientation of the amide NH relative to E95 2.65 and the THIQ core relative to the Cb atom of D80 2.50 at the intracellular side the OBS (Fig. 2E) .
Interestingly, the 3-and 6-carbon linker derivatives, MIPS1564 and MIPS1565, both displayed allosteric pharmacology and were sensitive to the mutation of E95 2.65 A, exhibiting a significant loss in functional affinity (Table 6 ). These results suggest that a linker length of 3 is sufficient to enable this interaction and allow the indole ring to be accommodated by the sub-pocket of SBP between TMs 2 and 7; and that extension of the linker length from 5 to 6 atoms may again allow a similar interaction, perhaps through additional flexibility within the linker region.
The influence of the SBP residue E95 2.65 on the affinity and cooperativity of SB269652 derivatives
Relatively subtle modifications to the 1H-indole-2-carboxamide SP of SB269652 cause a change in pharmacology from allosteric to that best fitted by a competitive model [9] . In particular, an Nmethyl amide derivative retains weak negative cooperativity suggesting that the presence of a hydrogen bond donating indolic NH but not the amide NH group was required for allosteric pharmacology [8, 9] . In order to understand how such subtle modifications can confer allosteric versus competitive pharmacology, we wanted to determine how such SP modifications changed the interaction with SBP residues and in particular E95 2.65 . The N-methyl amide derivative of SB269652, MIPS1531 exhibits a significant decrease of functional affinity at the E95 2.65 A mutant compared to WT, consistent with the loss of a hydrogen-bond interaction between the indole NH of this derivative and E95 2.65 . Replacement of the indole moiety with an 7-azaindole moiety (MIPS1588, Fig. 3, Table 6 ) that retains the constituents of the parent scaffold (a hydrogen-bond donating heteroatom and aromaticity of a biaryl system) causes a 12-fold improvement in affinity as compared to SB269652 and similar weak negative cooperativity with dopamine [9] . Furthermore, the results of our MD simulations indicate a significantly stronger interaction between the NH of the 7-azaindole moiety and E95 2.65 that may contribute to the higher affinity of this derivative compared to SB269652. Consistent with this computational finding, the affinity of this derivative is 27-fold lower at the E95 2.65 A mutant compared to the 13-fold loss observed for SB269652 (Table 6 , Fig. 3 ). Consistent with our previous SAR study [9] , replacement of the indole-2-carboxamide SP with pyrrole-2-carboxamide (MIPS1576, Fig. 3 ) results in pharmacology best fitted by a competitive rather than allosteric model (K B = 4 nM, Schild slope = 1.02 ± 0.08, Table 6 ). These ligands differ in the size of the SP whereby the pyrrole of MIPS1576 is smaller than the indole of SB269652. Despite this difference, our MD simulations show that the orientation of the aryl and amide NH groups of MIPS1588 and MIPS1576 relative to E95
2.65 are similar, although MIPS1576 made these interactions slightly more frequently during our simulations (Fig. 3) . Supporting this prediction, the pyrrole derivative displays a significant 24-fold loss in affinity at the E95 2.65
A mutant. Interestingly, how- ever, MIPS1576 showed pharmacology consistent with the action of a NAM at the E95
2.65
A mutant (ab = 0.06, Table 6 ).
3.7. Size of the orthosteric head group modulates the interaction with E95
We have previously demonstrated that the nature and size of the orthosteric head group is critical for the allosteric pharmacology of SB269652 [9] . Our results above indicate that the interaction of the SP with the SBP is a critical determinant of the negative cooperativity exerted by SB269652. We speculated that changes in the size of the orthosteric head group might confer a change in orientation of the SP within the SBP that would result in a change in sensitivity to the mutation E95 2.65 A. Replacement of the cyano group at the 7-position of the THIQ moiety with a hydrogen (MIPS1278) improves affinity and retains the weak cooperativity displayed by SB269652 (K B = 87 nM, ab = 0.09, Table 6 ) [9] . The increased affinity is complementary to the effect of S193 5.42 A mutation and supports our predicted SB269652 binding pose (see Discussion). Both the affinity and negative cooperativity of MIPS1278 (Table 6 ) are significantly attenuated at the E95 2.65 A mutant compared to WT (709-fold and 6-fold, respectively). This loss is consistent with an interaction between E95 2.65 and the indole NH for this derivative (Fig. 4) . Furthermore, the loss of affinity for MIPS1278 at the E95
A mutant is over 50-fold greater than that observed for SB269652, suggesting that without the cyano group the interaction between the indolic NH and E95 2.65 makes a greater relative contribution to affinity. Replacement of the cyano substituent with halogens of increasing size resulted in a progressive decrease in cooperativity [9] . However, the largest halogen introduced, a bromine substitution at the 7-position (MIPS1556), yielded pharmacology best fitted by a competitive model (K B = 724 nM, Schild slope = 1.31 ± 0.07, Table 6 ). We modelled and simulated MIPS1556 in a similar pose as SB269652 in the OBS, i.e., with the 7-Br substitution pointing towards S193 5.42 . Although an interaction between the indole group of fit by a competitive model at the wild type receptor but displayed a lower affinity at the E95 2.65 A mutant and weak negative cooperativity with dopamine. NA signifies that cooperativity could not be determined as data were best fit by a competitive model. Data represents the mean ± SD of four independent experiments. (Fig. 4) , we found the larger 7-Br substitution could not be accommodated in the same way as 7-CN and distorted the TM5 conformation (Fig. 4E) . We conclude that 7-Br-THIQ must adopt an alternative pose in the OBS, resulting in significantly different positions of the linker and thereby the SP, which does not favour the interaction between its SP and E95 2.65 . Consistent with this conclusion, no significant change in pharmacological parameters is observed at the E95 2.65 A mutant for MIPS1556 (Table 6 ).
Interaction with E95 2.65 does not determine allosteric versus competitive pharmacology
In our previous SAR study, removal of a hydrogen-bond donating heteroatom from the biaryl tail group of SB269652 appeared to confer competitive pharmacology [9] . While our initial study proposed an interaction between this hydrogen-bond donating heteroatom and E95 2.65 , the mutation E95
2.65
A does not cause a switch in the pharmacology of SB269652 from allosteric to competitive, but instead decreases both affinity and cooperativity. To investigate the importance of the interaction as a determinant of affinity and cooperativity of SB269652 and understand the effect of the E95 2.65 A mutation, we extended our study to derivatives that retain the aromaticity and planarity of the indole moiety yet lack a hydrogen-bond donating hetero-atom (Fig. 5, Table 6 ). Both the benzo[d]oxazole-2-carboxamide derivative (MIPS1528) and the indene analogue (MIPS1587) are unable to form a hydrogen bond between the SP and E95 2.65 , due to incorporation of an oxygen into the indole ring, or isoteric replacement of the indole with CH 2 respectively [9] . Both MIPS1528 and MIPS1587 display pharmacology best fitted by a competitive model at the WT D 2 R. While both ligands display a significant reduction in affinity at the E95 2.65 A mutant they nonetheless retain an apparently competitive mode of action (Table 6 ). Replacement of the indole moiety with a D-proline (MIPS1590) retains a NH-group within the SP that can participate in a hydrogen bond with E95 2.65 [9] . Furthermore, this prolyl NH will be positively charged at pH 7.4 as it is a secondary aliphatic amine. Indeed, while MIPS1590 exhibited apparent competitive pharmacology at both WT and E95
A, there was significant loss of affinity at E95 2.65 A that may reflect the loss of a salt bridge formed between the prolyl NH 2+ and this residue (Table 6 ). Therefore, the difference between the allosteric pharmacology of SB269652 and the competitive pharmacology of MIPS1590 is not solely related to an ability to interact with E95 2.65 , but instead suggests that the lack of planarity, aromaticity or the additional positive charge of the proline moiety as compared to the indole moiety prevents additional interactions required for the weak negative cooperativity of SB269652.
Discussion
The structure of the NAM SB269652 is similar to many ligands that display competitive pharmacology at the D 2 R [11, 12, 35] . The aim of this study was to systematically characterize the receptorligand interactions that govern the allosteric pharmacology of SB269652. Our recent SAR study found that changes to the 1H-indole-2-carboxamide SP of SB269652 resulted in significant changes in both affinity and cooperativity [9] . This study reveals that mutation of residues within the SBP predicted to interact with the SP caused significant decreases in negative cooperativity (V91 A mutation. Our MD simulations show that the SP of this derivative is oriented away from the SBP and instead occupies a subpocket of the SBP between TMs 2 and 3. Combined with our previous findings that the cis-isomer of SB269652 and truncated orthosteric derivatives of SB269652 that lack the SP all display competitive pharmacology, we conclude that interaction of the SP with the SBP between TMs 2 and 7 is a requirement for allosteric pharmacology [8] .
A hydrogen-bond interaction between the indolic NH of SB269652 and E95 2.65 within the SBP was proposed to be a particularly important determinant of affinity and cooperativity [8, 9] . In this study, all SB269652 derivatives that displayed allosteric pharmacology at the WT D 2 R exhibited a loss of affinity and negative cooperativity at the E95 A mutation significantly affects the overall shape and size of the SBP, resulting in new poses for SB269652 (Verma et al., manuscript in preparation) that likely contribute to changes in affinity and cooperativity at this mutant. Thus, while interaction with the SBP appears to be required for allosteric pharmacology, sensitivity to this mutation alone is not a predictor of allosteric versus competitive action.
Our SAR study, based on observations that proline and pyrrole derivatives display apparently competitive pharmacology at the WT D 2 R, provided evidence that the size, aromaticity and planarity of the 1H-indole-2-carboxamide tail of SB269652 are determinants of the allosteric pharmacology of SB269652 [8] . Both derivatives display lower affinity at the E95 2.65 A D 2 R. The lack of aromaticity of the proline derivative and/or the positive charge of the prolyl NH confers apparently competitive behaviour but retains an interaction with E95 2.65 . However, the pyrrole derivative displays allosteric pharmacology at this mutant. Our molecular modelling experiments predict that the positions of the amide and aryl NH [8] . If, rather than being competitive with dopamine, MIPS1576 displays high negative cooperativity, the switch in pharmacology of MIPS1576 from apparently competitive (WT) to allosteric (E95 2.65 A) may be consistent with the decrease in negative cooperativity observed for SB269652. If this mechanism is correct, this would suggest that, rather conferring competitive antagonism, the smaller size of the pyrrole-2-carboxamide (MIPS1576) SP leads to an increase in affinity and negative cooperativity. Our previous modelling study predicted a salt bridge interaction between the highly conserved OBS residue D114
3.32 and the protonated tertiary amine of the THIQ moiety of SB269652. Evidence for such an interaction was inferred from the competitive action of fragments of SB269652 (MIPS1059 and MIPS1071) that contain the THIQ moiety [8] . In agreement with this hypothesis, the mutation D114 3.32 E confers a 100-fold loss of affinity for these fragments. However, while we observe a close interaction between this protonated aliphatic amine and D114
3.32 for all full-length SB269652 derivatives studied in our modelling experiments (Figs. 1-4 ), SB269652 exhibited a loss of cooperativity but no loss of affinity at this mutant. It should be noted, however, that D114 3.32 E is a relatively conservative mutation and the loss of affinity for the orthosteric antagonist [ 3 H]spiperone at this mutant was a modest 6-fold. Thus it is feasible that the protonated tertiary amine of the THIQ moiety of SB269652 may be able to maintain an interaction with this residue and/or that the loss of affinity conferred by this mutation may be compensated by the gain of other interactions. In agreement with this hypothesis, MIPS1868, a fulllength derivative with preserved allosteric properties displayed a modest 4-fold loss of affinity at this moiety. This suggests that the THIQ moiety of this extended compound makes a salt bridge interaction with D114 3.32 , and that the addition of the SP confers additional contacts within the SBP and/or a reorientation of the PP within the OBS that reduces the impact of this mutation relative to the larger effect observed for the truncated orthosteric fragments. Therefore, the interaction of the SP of SB269652 with the SBP likely minimises the impact of the D114 3.32 E mutation upon affinity.
In the absence of a radiolabelled derivative of SB269652, or biophysical approaches to measure the binding of SB269652 directly, we must rely on the use of orthosteric 'probe' ligands to detect the effect of mutations upon the pharmacology of SB269652. This limits our choice of mutations to those that do not abrogate probe binding -indeed, with the exception of D114 3.32 E on MIPS1868) none of the mutations decreased the affinity of SB269652. Instead, we observed changes in cooperativity and/or increases in affinity. Such mutations may change the orientation of the ligand within both the OBS and SBP such that loss of a contact within one pocket is compensated by gains of contacts within the other pocket leading to increases in affinity and changes in negative cooperativity. The mutation S193 5.42 A conferred an increase in the affinity of SB269652, as did the replacement of the 7-cyano substitution of SB269652 with hydrogen (MIPS1278). Our MD simulations indicate that the 7-cyano substituent is orientated towards S193 5.42 and we speculate that both changes allow the THIQ moiety to adopt a more favourable position within the OBS. Consistent with the hypothesis that the change in orientation within the OBS will modulate interactions within the SBP, MIPS1278 displayed a 50-fold higher sensitivity to the SBP mutation E95 2.65 A than SB269652. Indeed, the results of our MD simulations suggest the 7-cyano substitution may weaken the interaction between the indolic NH and E95 2.65 ( Fig. 4 and Draper-Joyce et al. manuscript in preparation). Thus, we speculate that stabilizing this interaction in the SBP by removing the 7-cyano substituent may, in part, contribute to the increased affinity of MIPS1278 as compared to SB269652.
In summary, by integrating the findings of our previous SAR results of SB269652 with this mutagenesis study we have systematically characterized a bitopic-binding mode that extends from the OBS into a SBP. We provide further evidence that interaction of the SP of SB269652 with the SBP is a requirement for allosteric pharmacology and show how changes to the THIQ moiety or the SP can lead to increases in affinity. We also reveal how changes to interactions within one pocket can modulate interactions in the other pocket. The orientation of SB269652 within both pockets likely determines allosteric pharmacology. A recent study of extended D 2 R partial agonists illustrated how the interactions made by a secondary pharmacophore within the SBP can alter the orientation of the orthosteric moiety within the OBS that, in turn, modulated intrinsic agonist efficacy [12] . Extended or bitopic D 2 R compounds have been shown to display distinct and desirable characteristics such as subtype-selectivity, biased agonism and allostery [8, 12, [36] [37] [38] . Understanding how such extended modes of interaction dictate these different pharmacological profiles is important for the design of novel selective ligands for this receptor.
